Is the Rule of Law an Antidote for Religious Tension? The Promise and Peril of Judicializing Religious Freedom

Although “rule of law” is often regarded as a solution for religious conflict, this article analyzes the role of legal processes and institutions in hardening boundaries and sharpening antagonisms among religious communities. Using case studies from Sri Lanka, India, Malaysia, and Pakistan, we highlight four specific mechanisms through which legal procedures, structures, and instruments can further polarize already existing religious conflicts. These mechanisms include the procedural requirements and choreography of litigation (Sri Lanka), the strategic use of legal language and court judgments by political and socioreligious groups (India), the activities of partisan activists who mobilize around litigation (Malaysia), and the exploitation of “public order” laws in contexts framed by antagonism targeting religious minorities (Pakistan)

Finding a cure for tuberous sclerosis complex: from genetics through to targeted drug therapies

Tuberous sclerosis complex (TSC) is a rare, autosomal dominant genetic condition caused by a mutation in either the TSC1 or TSC2 gene. Phenotypically, this leads to aberrant cell growth and the formation of benign tumors called hamartomas in multiple organs. Understanding the mechanisms of pathology that are caused through the presence of disease causing mutations is a real hurdle for many rare genetic disorders; a limiting factor that restricts knowledge of the disease and any hope of a future cure. Through the discovery of the TSC1 and TSC2 genes and the signaling pathways responsible for the pathology of TSC, a new drug target called mechanistic target of rapamycin complex 1 (mTORC1) was discovered. Rapamycin, an mTORC1 inhibitor, is now the only pharmacological therapy approved for the treatment of TSC. This chapter summarizes the success story of TSC and explores the future possibilities of finding a cure

Role of Middle T-Small T in the Lytic Cycle of Polyomavirus: Control of the Early-to-Late Transcriptional Switch and Viral DNA Replication

A comparative analysis of the lytic cycle of wild-type polyomavirus and middle T and small T defective mutants was carried out in the A2 genetic background. The results contrast with those obtained in comparisons between the hr-t type and their middle-T small-T-producing partners as previously described (20). The A2-derived mutants were found to share the maturation defect previously described for the hr-t mutants. However, their defect in DNA replication was more acute, resulting in a 5- to 100-fold decrease in the accumulation of viral genomes. Furthermore, their gene expression pattern was affected. A2-derived mutants displayed an early defect resulting in a 4- to 16-h delay in the expression of large T, and an alteration of the early-to-late transcriptional switch. In wild-type A2 infection, this switch is characterized by a large increase in the accumulation of early transcripts followed by late transcripts after the appearance of middle T and small T proteins and the onset of viral DNA replication (L. Chen and M. M. Fluck, J. Virol. 75: 8368–8379, 2001). In the mutant infection, increases in both classes of transcripts were delayed and reduced, but the effect on early transcripts was more pronounced. As has been described previously for the hr-t mutants (E. Goldman, J. Hattori, and T. Benjamin, Cell 13:505–513, 1979), the magnitude of these defects depended upon experimental conditions. Experiments using cytosine β-arabinofuranoside to reduce genome amplification suggest that the effect of middle T-small T on the transcriptional switch is not solely mediated by the effect of these protein(s) on increasing the number of templates. These data provide the first direct demonstration of an effect of middle T and/or small T in the viral transcription pattern during viral infection. The results agree with previous results obtained with plasmid reporters and with our understanding that the downstream targets of the middle T signaling pathway include three transcription factors that have binding sites in the enhancer domain that play a key regulatory role in the expression of the viral genes